Background: Children with high-risk neuroblastoma are exposed to multimodality therapies early in life and survivors confront late therapy-related toxicities. This study assessed respiratory symptoms, pulmonary function tests (PFTs), and risk factors for abnormalities among survivors.
W
ith advances in cancer therapies, there is a growing population of survivors of childhood cancer. 1, 2 Data from the Childhood Cancer Survivor Study demonstrate that survivors have an increased risk of lung fibrosis, recurrent pneumonia, chronic cough, pleurisy, requirement for supplemental oxygen, and exercise-induced shortness of breath more than 5 years post-diagnosis. 3, 4 Increased mortality due to pulmonary causes among cancer survivors has also been reported. 5 Limited information is available on pulmonary outcomes in survivors of high-risk neuroblastoma (NB). [6] [7] [8] Studies investigating late effects of cancer therapies have linked specific chemotherapeutic agents, radiation therapy (RT), and hematopoietic stem cell transplant (HSCT) to late pulmonary toxicities. 3, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Late respiratory complications of antineoplastic treatments have been described in children. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] 25 In addition, studies have suggested that exposure to some cancer therapies very early in life may increase the risk for long-term sequelae. 13, 28 Children with high-risk NB are exposed to multimodality therapies very early in life, and may therefore have a higher risk for developing pulmonary complications including subclinical abnormalities in lung function. Pulmonary outcomes among high-risk NB survivors have not been well-described and results of pulmonary function testing (PFTs) in long-term survivors of NB are limited. This study aimed to examine late pulmonary outcomes and measure PFTs among a large group of high-risk NB survivors followed at a single institution with the hypothesis that chronic respiratory symptoms and abnormalities in lung function are common and specific risk factors may predict late respiratory abnormalities.
MATERIALS AND METHODS
This was a cross-sectional study that assessed respiratory conditions and PFTs among pediatric survivors of high-risk NB. Children aged 6 to 21 years who had survived high-risk NB (stage 3 or 4), were alive and disease free at least 1 year after completion of treatment, were evaluated at least once in the long-term follow-up (LTFU) clinic at Memorial Sloan Kettering Cancer Center (MSKCC) between 2012 and 2015, and were able to cooperate with the testing procedures, were eligible for study participation.
Demographic data and therapeutic exposures were abstracted from the MSKCC medical record. RT to the chest included the mediastinum, chest wall, thoracic spine, and whole lungs. Thoracic surgery was defined as thoracotomy for tumor or lymph node resection and/or resection of lung tissue, but did not include thoracoabdominal exploration only. After providing informed consent, parents or guardians of study participants were asked to complete a self-administered questionnaire (Supplemental Digital Content 1, http://links.lww.com/ JPHO/A207 Supplemental Digital Content 2, http://links. lww.com/JPHO/A208). Questions included assessments of (1) pulmonary conditions including chronic cough, shortness of breath, wheeze, bronchitis, pneumonia, and oxygen use; (2) history of allergy and asthma symptoms for the study participant and close family members; and (3) exposure to potential environmental triggers of respiratory disease. Questionnaires did not assess treatment exposures or therapies for lung disease other than use of supplemental oxygen. Chronic respiratory symptoms were defined as symptoms present with frequency Z2 d/wk or Z2 nights per month for at least 3 months of the past year. Subjects who were 12 years or older completed an additional questionnaire regarding self-reported respiratory symptoms and/or environmental exposures in the month before the visit.
PFTs were assessed at the Pediatric PFT laboratory at Weill Cornell Medical College. Spirometry, plethysmography, and diffusion capacity of the lung for carbon monoxide (DLCO) were measured (Vmax Encore; Viasys, Yorba Linda, CA). DLCO was assessed using the single breath method. Airway responsiveness was tested by repeating spirometry 15 minutes after albuterol administration. National Health and Nutrition Examination Survey III reference equations by ethnic group were used to generate percent predicted values. 29 Normal PFT parameters were defined as percent predicted values Z80. Definitions of PFT abnormalities adhered to the American Thoracic Society/European Respiratory Society guidelines. 29 Abnormalities in forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) were defined by percent predicted values as follows: (1) mild: 70 to 79; (2) moderate: 60 to 69; (3) moderately severe: 50 to 59; (4) severe: 35 to 49; (5) very severe: <35. 29 Abnormalities in total lung capacity (TLC) were defined by percent predicted values as follows: (1) mild: 70 to 79; (2) moderate: 60 to 69; (3) severe: <60. Abnormalities in DLCO were defined by percent predicted values as follows: (1) mild: 61 to 79; (2) moderate: 40 to 60; (3) severe: <40. 29 Obstructive disease was defined as FEV1/FVC < 0.8. Restrictive disease was defined by percent predicted TLC < 80.
Descriptive statistics were calculated for demographic and treatment variables and medical complications including PFT abnormalities. Bivariate analyses were used to determine associations between potential risk factors, such as age at treatment and time since completion of therapy, and PFT abnormalities and/or respiratory symptoms using 2-sample t test, w 2 or Fisher exact tests as appropriate. All statistical tests were 2-sided, with a significance level of P < 0.05. Unadjusted odds ratios and 95% confidence intervals were not computed due to small or zero cell counts for a number of the bivariate analyses. Row percentages were calculated instead. All analyses were conducted with SAS version 9.3 (SAS Institute Inc., Cary, NC). 
RESULTS
A total of 214 NB survivors aged 6 to 21 years are followed in the LTFU clinic; the majority of survivors were treated for high-risk NB. Thirty-nine survivors of high-risk NB were enrolled in the study. No subjects were excluded from participation due to developmental delay or behavioral issues. Study participants were diagnosed between 1996 and 2009. Characteristics of study participants are shown in Table 1 . Chronic respiratory symptoms were reported for 33% of the subjects and included exercise-induced respiratory symptoms (n = 16), cough (n = 10), congestion/phlegm *Ethnicity was self-reported at time of study participation. wAgents administered to only 1 subject are not listed and include: celebrex, cytarabine, dacarbazine, L-asparaginase, lenalidomide, octreotide, and thalidomide.
zMedian RT dose: 2100 cGy (range, 900 to 2160 cGy). yAnti-GD2 antibody included: 3F8, 03-077, and ch14.18. 8IntraOmmaya compartmental radioimmunotherapy for CNS metastases included:
(n = 5), shortness of breath (n = 5), and wheeze (n = 4). A physician-diagnosed respiratory condition at any time was reported for 38% and included asthma (n = 8), recurrent pneumonia (n = 4), pulmonary fibrosis or "scarring" (n = 2), and use of supplemental oxygen (n = 4).
Among the 14 study participants 12 years or older, 93% reported respiratory symptoms in the past month. The frequency of respiratory symptoms included every day (29%), several days in a week (21%), a few days of the month (29%), and only when sick with a cold (14%). Selfreported respiratory symptoms included cough (12/14), shortness of breath (7/14), congestion/phlegm (8/14), wheeze (2/14), and exercise-induced symptoms (2/14). Although no adolescent survivors of NB reported that they smoke, 13% of all study participants had exposure to cigarette smoke in the home.
PFT abnormalities were noted in 79% of participants. Restriction was identified in 41%, obstruction in 8%, and mixed obstructive and restrictive defect in 3%. The most common abnormalities were low FEV1 (38%), decreased TLC (44%), and reduced DLCO (67%). The number of subjects with abnormal lung function parameters by severity can be seen in Table 2 . There were no associations between chronic respiratory symptoms and abnormal PFT parameters.
In bivariate analysis, a number of risk factors were associated with PFT abnormalities as seen in Table 3 . Significant associations were seen between subjects treated with thoracic surgery and decreased FVC (100.0% vs. 39.4% for thoracic surgery vs. no thoracic surgery, respectively; P = 0.008) and FEV1 (83.3% vs. 30.3% for thoracic surgery vs. no thoracic surgery, respectively; P = 0.024), chest RT and decreased FVC (85.7% vs. 40.6% for chest RT vs. no chest RT, respectively; P = 0.044), and thoracic surgery plus chest RT and decreased FVC (100.0% vs. 42.9% for thoracic surgery plus chest RT vs. no thoracic surgery plus chest RT, respectively; P = 0.047) and FEV1 (100.0% vs. 31.4% for thoracic surgery plus chest RT vs. no thoracic surgery plus chest RT, respectively; P = 0.020). There were no associations between thoracic surgery, chest RT, or thoracic surgery plus chest RT and abnormal TLC. There were weak associations between chest RT and decreased FEV1 (71.1% vs. 31.3% for chest RT vs. no chest RT, respectively; P = 0.085) and DLCO (100.0% vs. 67.7% for chest RT vs. no chest RT, respectively; P = 0.157), as well as HSCT and low FEV1 (50.0% vs. 23.5% for HSCT vs. no HSCT, respectively; P = 0.092). Participants with normal DLCO had longer time intervals since completion of their cancer therapy compared with those with abnormal DLCO (8.34 compared with 5.73 y, respectively; P = 0.033).
As seen in Table 4 , subjects exposed to thoracic surgery had decreased mean FVC compared with subjects with no thoracic surgery (P = 0.052) and those treated with chest RT had lower mean TLC compared with subjects with no chest RT (P = 0.054). Subjects exposed to each potential risk factor (compared with the absence of the risk factor), other than smoking, had lower mean FVC and FEV1 (statistical trends indicated; Pr0.200). Subjects exposed to thoracic surgery (compared with no thoracic surgery) and thoracic surgery plus chest RT (compared with no thoracic surgery plus chest RT) had decreased mean TLC (statistical trends indicated; P = 0.060 and 0.090, respectively).
In addition, there were significant associations between treatment exposures and respiratory symptoms and conditions as seen in Table 5 . Parents of subjects treated with HSCT were more likely to report chronic shortness of breath (23.8% vs. 0.0% for HSCT vs. no HSCT, respectively; P = 0.053). Exposure to cigarette smoke in the home was associated with chronic respiratory symptoms (80.0% vs. 27.3% for cigarette smoke vs. no cigarette smoke, respectively; P = 0.038), with a weaker association with a physician-diagnosed chronic respiratory condition (80.0% vs. 33.3% for cigarette smoke vs. no cigarette smoke, respectively; P = 0.063). No associations between the age at diagnosis or cyclophosphamide dose and PFT abnormalities or reported chronic respiratory symptoms or conditions were seen.
DISCUSSION
Here we report the late pulmonary toxicities among pediatric survivors of high-risk NB. Respiratory conditions and mild and moderate PFT abnormalities were common in this cohort. Risk factors for respiratory abnormalities included treatment with thoracic surgery, chest RT, thoracic surgery plus chest RT, and shorter time since completion of therapy.
Approximately one third of subjects reported chronic respiratory symptoms in the past year and the presence of a physician-diagnosed respiratory condition ever. This differs from a prior study that described respiratory symptoms among two thirds of pediatric survivors of high-risk NB, with 3 of 18 reporting severe respiratory symptoms. 8 These patients were treated in the late 1980s with high-dose chemotherapy, total body irradiation (TBI), and autologous HSCT. 8 Although the number of subjects in the earlier study is small, the higher prevalence of respiratory symptoms may suggest that newer treatment modalities are less likely to cause severe pulmonary toxicity. Notably, no subjects in our cohort received TBI and only 1 subject was treated with whole lung irradiation, both of which have been associated with late adverse pulmonary outcomes. 16, 27, 30 Although 93% of adolescent subjects in our cohort reported respiratory symptoms in the past month, only half (7/14) reported frequent symptoms (daily or several days of the week). Adolescent questionnaires did not ask about self-reported chronic respiratory symptoms, preventing a direct comparison with parental-reported data.
PFT abnormalities were common in our study, corresponding with studies of adult survivors of childhood cancer. 31, 32 Interestingly, in this cohort, PFT impairments were mostly mild to moderate in severity. The most common abnormality was decreased DLCO. Decreased DLCO was associated with shorter times since completion of therapy, which suggests that diffusion capacity may improve over time. This may reflect transient interstitial lung disease related to cancer therapies versus a transient reduction in lung volume, although a similar relationship between TLC and time since completion of therapy was not seen. A similar pattern of normalization of impaired DLCO from 6 months to 4 years following treatment for stage 4 NB with high-dose chemotherapy, TBI, and autologous HSCT was previously seen. 8 Mild transient declines in DLCO have also been reported in children with other forms of neoplastic disease treated with HSCT. 14, 18 Recent data from adult survivors of childhood cancer reveal a decline in DLCO over more extended time periods (median 17 to 22 y since diagnosis, respectively). 32, 33 Pulmonary toxicities have been associated with antineoplastic agents and HSCT in multiple populations with neoplastic disease. Chest RT as well as chemotherapeutic agents such as bleomycin, mitomycin-C, carmustine, busulfan, and cyclophosphamide can cause pneumonitis and interstitial lung injury acutely in addition to pulmonary fibrosis and other lung toxicities over time. 3, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Multiple studies have reported late PFT abnormalities after HSCT, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] and lung function impairment has been described among pediatric patients. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] 25 Here we identified weak associations between HSCT and chronic shortness of breath as well as abnormal FVC and FEV1. In addition, exposure to thoracic surgery, chest RT, and thoracic surgery plus chest RT were associated with abnormal lung function. There were weak associations between chest RT and PFT abnormalities. Chest RT was previously identified as a risk factor for developing pulmonary problems among advanced stage NB survivors 6 and is a risk factor for abnormal PFTs among adult survivors of childhood cancer. [31] [32] [33] The small number of subjects treated with chest RT in our cohort may have limited our power to detect any significant associations with PFT abnormalities. We did not find an association between age at diagnosis and respiratory symptoms or PFT abnormalities. Earlier studies in other pediatric cancer populations have identified associations between age at treatment exposure and late pulmonary outcomes, 33 including associations between exposure to carmustine therapy at a young age and severe pulmonary fibrosis and increased mortality 13 as well as chest RT at a young age and PFT abnormalities. 10 In addition, studies of adult survivors of childhood cancer have revealed associations between age at diagnosis and PFT abnormalities. 32, 33 The absence of similar findings in our cohort may again be related in part to the small number of subjects treated with chest RT.
It is reassuring that none of the adolescent survivors of high-risk NB in this study self-reported smoking cigarettes although this may not accurately reflect behavior patterns. We found chronic respiratory symptoms to be more common among children exposed to second hand smoke at home although the exposure group was small. Studies of adult survivors of childhood cancer reveal lower smoking rates than in the general population 4, 34, 35 and minor differences in smoking prevalence based on exposure to cardiopulmonary toxic therapies; this suggests differences in behavior based on perceived risk. 34 Further studies are needed to determine if knowledge of subclinical decreases in PFT parameters prevent smoking initiation among adolescent or young adult survivors of high-risk NB.
Limitations to this study include the use of nonvalidated questionnaires. In addition, 62% of subjects were enrolled in the summer months, perhaps leading to an underreporting of chronic respiratory symptoms. Adolescent questionnaires collected data on respiratory symptoms present in the past month, thereby preventing a direct comparison with parental-reported chronic respiratory symptoms. The cross-sectional design of this study prevents any conclusions regarding patterns in lung function over time. The small number of subjects in this cohort limited the risk factor analyses. The role of exposure to specific alkylating drugs could not be assessed because a large number of subjects were exposed to many of the same agents. Similarly, the role of immunotherapy on pulmonary outcomes could not be studied since all but 2 subjects were treated with either anti-GD2 antibody alone or in conjunction with GD2/GD3 vaccine. The significance of the association between thoracic surgery and chest RT and decreased forced flow rates is unclear given the absence of associations with decreased TLC. In addition, the small number of study subjects did not allow for multivariate analyses of potential confounders. Moreover, not all survivors are followed at the LTFU clinic and this small cohort of survivors may not be representative of survivors overall.
Late pulmonary sequelae in children following treatment for high-risk NB early in life are common. Almost all children in this study had abnormal PFTs and one third reported chronic respiratory symptoms. Survivors of highrisk NB should be screened for respiratory symptoms and PFT abnormalities. Further studies, including longitudinal assessments of lung function and measurements of exercise capacity are needed to better characterize the true extent of pulmonary disabilities in this at-risk population.
